Citi Pharma partners with Indian pharma company

KARACHI: Citi Pharma Limited has entered into an agreement with an Indian company to get high-quality active pharmaceutical ingredients (APIs) and products for the Pakistani market.

Citi Pharma announced in a notice to the Pakistan Stock Exchange (PSX) on Tuesday that it entered into an agreement with Murli Krishna Pharma Private Ltd, a company incorporated and existing under the relevant laws of India. “This exclusive strategic partnership aims to establish the terms and conditions under which Murli Krishna Pharma Private Ltd will supply high-quality Active Pharmaceutical Ingredients (APIs) and products exclusively to Citi Pharma Limited in the Pakistan market,” read the notice. It said that under the terms of this agreement, Murli Krishna Pharma Private Ltd has agreed not to supply any of the APIs in N-1 form (the form they will be supplying to Citi Pharma) to any other company in Pakistan except City Pharma. “This exclusivity ensures that Citi Pharma Limited will have the sole right to market, distribute and sell these exclusive products within Pakistan,” it said.

Murli Krishna Pharma Private Ltd is committed to supplying the exclusive products to Citi Pharma Limited in accordance with the highest quality standards in the pharmaceutical industry, complying with British Pharmacopoeia (BP) or United States Pharmacopeia (USP) standards, or as specified by Citi Pharma’s regulatory team. “This commitment to quality and exclusivity is a significant milestone for both companies and underscores our dedication to providing the best pharmaceutical products to the market,” read the notice.